The specificity and sensitivity of the developed and evaluated CBPP mAbs show that two of them (P2B1 and P3C1) have the potential to be utilized for the development of an ELISA test against CBPP antigen, while one mAb demonstrated that it can be utilized for the development of a rapid immunocapture test for immediate infection. The gene discussed is CELA3B; the disease is infection.